STAT Plus Next up for KRASblocking cancer drug fans a hugely important data reveal from Mirati Therapeutics

STAT Plus: Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics

After Amgen's impressive tumor-shrinking data from its KRAS-targeted cancer drug, attention shifts to Mirati Therapeutics and its competing KRAS blocker.

More From BioPortfolio on "STAT Plus: Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics"